Ruben Hartkoorn

Cette personne n’est plus à l’EPFL

À propos
Confidentialité
Mentions légales

Graph Chatbot

Publications associées (31)

Synthesis and Antimycobacterial Activity of 2,1 '-Dihydropyridomycins

Stewart Cole, Ruben Hartkoorn

Dihydropyridomycins 2 and 3, which lack the characteristic enol ester moiety of the potent antimycobacterial natural product pyridomycin (1), have been prepared from L-Thr, R- and S-hydroxy isovaleric acid, and 3-pyridinecarboxaldehyde. The 2R isomer 2 sho ...

Amer Chemical Soc2013

In Vitro Combination Studies of Benzothiazinone Lead Compound BTZ043 against Mycobacterium tuberculosis

Stewart Cole, Ruben Hartkoorn, Benoit Lechartier

Benzothiazinones (BTZ) are a new class of drug candidates to combat tuberculosis that inhibit decaprenyl-phosphoribose epimerase (DprE1), an essential enzyme involved in arabinan biosynthesis. Using the checkerboard method and cell viability assays, we hav ...

Amer Soc Microbiology2012

Virulence Regulator EspR of Mycobacterium tuberculosis Is a Nucleoid-Associated Protein

Benjamin Blasco, Stewart Cole, Claudia Sala, Florence Pojer, Jeffrey Chen, Swapna Uplekar, Jacques Rougemont, Ruben Hartkoorn

The principal virulence determinant of Mycobacterium tuberculosis (Mtb), the ESX-1 protein secretion system, is positively controlled at the transcriptional level by EspR. Depletion of EspR reportedly affects a small number of genes, both positively or neg ...

Public Library of Science2012

Genome-Wide Definition of the SigF Regulon in Mycobacterium tuberculosis

Stewart Cole, Claudia Sala, Swapna Uplekar, Jacques Rougemont, Ruben Hartkoorn, Philippe Busso

In Mycobacterium tuberculosis the alternative sigma factor SigF controls the expression of a particular subset of genes by altering RNA polymerase specificity. Here, we utilize two genome-wide approaches to identify SigF-binding sites: chromatin immunoprec ...

American Society for Microbiology2012

Streptomycin-Starved Mycobacterium tuberculosis 18b, a Drug Discovery Tool for Latent Tuberculosis

Stewart Cole, Neeraj Dhar, Claudia Sala, Ruben Hartkoorn, Ming Zhang

Mycobacterium tuberculosis 18b, a streptomycin (STR)-dependent mutant that enters a viable but nonreplicating state in the absence of STR, has been developed as a simple model for drug testing against dormant bacilli. Here, we further evaluated the STR-sta ...

Amer Soc Microbiology2012

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid

Stewart Cole, Claudia Sala, Florence Pojer, Sophie Magnet, Swapna Uplekar, Ruben Hartkoorn, Joao Pedro De Almeida Neres, Raju Mukherjee

Tuberculosis, a global threat to public health, is becoming untreatable due to widespread drug resistance to frontline drugs such as the InhA-inhibitor isoniazid. Historically, by inhibiting highly vulnerable targets, natural products have been an importan ...

Wiley Open Access2012

Tuberculosis drugs: new candidates and how to find more

Claudia Sala, Ruben Hartkoorn

The recent years have witnessed significant progress in the development of new drug candidates for the treatment of TB. While many of these are now in clinical trials, continued research is needed in order to sustain the drug discovery pipeline and meet th ...

2011

A Simple Model for Testing Drugs against Non-replicating Mycobacterium tuberculosis

Stewart Cole, Neeraj Dhar, Claudia Sala, Ruben Hartkoorn, Ming Zhang

Non-replicating or dormant cells of Mycobacterium tuberculosis constitute a challenge to tuberculosis (TB) therapy because of their tolerance or phenotypic resistance to most drugs. Here, we propose a simple model for testing drugs against non-growing cell ...

2010

Leads for antitubercular compounds from kinase inhibitor library screens

Gerardo Turcatti, Marc Chambon, Damiano Banfi, Stewart Cole, Sophie Magnet, Ruben Hartkoorn, Edina Rita Székely

Discovering new drugs to treat tuberculosis more efficiently and to overcome multidrug resistance is a world health priority. To find antimycobacterial scaffolds, we screened a kinase inhibitor library of more than 12,000 compounds using an integrated stra ...

2010

Sigma Factor F does not Prevent Rifampin Inhibition of RNA Polymerase or Cause Rifampin Tolerance in Mycobacterium tuberculosis

Stewart Cole, Claudia Sala, Florence Pojer, Sophie Magnet, Jeffrey Chen, Ruben Hartkoorn

The tolerance of Mycobacterium tuberculosis to anti-tuberculosis drugs is a major reason for the lengthy therapy needed to treat a tuberculosis infection. Rifampin is a potent inhibitor of RNA polymerase (RNAP) in vivo, but has been shown to be less effect ...

American Society for Microbiology2010

Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC

Ruben Hartkoorn

center dot Antiretroviral protease inhibitors such as lopinavir and saquinavir have been shown to be substrates of ABCB1. Co-administration with the potent ABCB1 and CYP3A4 inhibitor, ritonavir, has shown improved pharmacokinetics and subsequent therapeuti ...

2009

Page 2 sur 2